{"id":6587,"text":"According to Traditional Chinese Medicine theory, influenza is categorized as a warm disease or Wen Bing.","label":[[25,32,"Ethnic group"],[50,92,"Pathology"]],"Comments":[]}
{"id":6588,"text":"The Wen Bing formulas, such as Yin-Qiao-San and Sang-Ju-Yin, are still first-line herbal therapies in combating variant influenza virus.","label":[[4,21,"Herb name"],[31,43,"Herb name"],[48,59,"Herb name"],[120,135,"Pathology"]],"Comments":[]}
{"id":6589,"text":"To continue our study on the pharmacokinetic and pharmacodynamic interactions between Wen Bing formulas and oseltamivir (OS), the first-line western drug for the treatment of influenza, further interactions between OS and the eight single herbs and their relevant marker components from Wen Bing formulas were investigated in the current study.","label":[[86,103,"Herb name"],[108,124,"Drug"],[175,184,"Pathology"],[215,217,"Drug"],[287,304,"Herb name"]],"Comments":[]}
{"id":6590,"text":"To establish an in-vitro screening platform for investigation of the potential anti-influenza herbs\/herbal components that may have pharmacokinetic and pharmacodynamic interactions with OS.","label":[[16,34,"Study"],[84,93,"Pathology"],[186,188,"Drug"]],"Comments":[]}
{"id":6591,"text":"To screen potential inhibition on OS hydrolysis, 1 μg\/mL of OS is incubated with herbs\/herbal components in diluted rat plasma, microsomes and human recombinant carboxylesterase 1(hCE1) under optimized conditions.","label":[[34,36,"Drug"],[60,62,"Drug"],[143,186,"Target"]],"Comments":[]}
{"id":6592,"text":"MDCK-WT and MDCK-MDR1 cell lines are utilized to identify potential modification on P-gp mediated transport of OS by herbs\/herbal components.","label":[[84,107,"Target"],[111,113,"Drug"]],"Comments":[]}
{"id":6593,"text":"Caco-2 cells with and without Gly-Sar inhibition are performed to study the uptake of OS via PEPT1 transporters.","label":[[86,88,"Drug"],[93,111,"Target"]],"Comments":[]}
{"id":6594,"text":"Modification on OAT3 mediated transport is verified by the uptake of OS on HEK293-MOCK\/HEK293-OAT3 cells.","label":[[16,20,"Target"],[69,71,"Drug"],[94,98,"Target"]],"Comments":[]}
{"id":6595,"text":"Anti-virus effects were evaluated using plaque reduction assay on H1N1 and H3N2 viruses.","label":[],"Comments":[]}
{"id":6596,"text":"Potential pharmacokinetic and pharmacodynamic interaction between OS (30 mg\/kg) and the selected herb, Radix Scutellariae (RS), at 300–600 mg\/kg were carried out on rats.","label":[[66,68,"Drug"],[70,78,"Amount"],[103,126,"Herb name"],[131,144,"Amount"]],"Comments":[]}
{"id":6597,"text":"All samples are analyzed by an LC\/MS\/MS method for the contents of OS and OSA.","label":[[67,69,"Drug"],[74,77,"Drug"]],"Comments":[]}
{"id":6598,"text":"A mechanistic PK model was developed to interpret the HDI between OS and RS in rats.","label":[[66,68,"Drug"],[73,75,"Herb name"]],"Comments":[]}
{"id":6599,"text":"Our developed platform was successfully applied to screen the eight herbal extracts and their ten marker components on metabolic inhibition of OS and modification of OS transport mediated by P-gp, OAT3 and PEPT1.","label":[[143,145,"Drug"],[166,168,"Drug"],[191,195,"Target"],[197,201,"Target"],[206,211,"Target"]],"Comments":[]}
{"id":6600,"text":"Results from six in-vitro experiments were analyzed after converting raw data from each experiment to corresponding fold-change (FC) values, based on which Radix Scutellariae (RS) were selected to have the most HDI potential with OS.","label":[[17,37,"Study"],[156,179,"Herb name"],[230,232,"Drug"]],"Comments":[]}
{"id":6601,"text":"By analyzing the plasma and urine pharmacokinetic data after co-administration of OS with a standardized RS extract in rats using an integrated population pharmacokinetics model, it is suggested that RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which leads to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine.","label":[[82,84,"Drug"],[105,107,"Herb name"],[200,202,"Herb name"],[217,219,"Drug"],[287,289,"Drug"],[329,331,"Drug"],[361,364,"Drug"]],"Comments":[]}
{"id":6602,"text":"Never the less, the anti-virus effects of 2.5 h post-dose rat plasma were not influenced by co-administration of OS with RS.","label":[[113,115,"Drug"],[121,123,"Herb name"]],"Comments":[]}
{"id":6603,"text":"A six-dimension in-vitro screening platform has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.","label":[[16,34,"Study"],[96,98,"Herb name"],[161,163,"Drug"]],"Comments":[]}
{"id":6604,"text":"Although co-administered RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which lead to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine, the anti-virus effect of OS was not influenced by co-administered RS.","label":[[25,27,"Herb name"],[42,44,"Drug"],[112,114,"Drug"],[153,155,"Drug"],[185,188,"Drug"],[244,246,"Drug"],[285,287,"Herb name"]],"Comments":[]}
{"id":6605,"text":"Fraction of absorbed Confidence intervals Clearance Electrospray ionization Fold change Remaining fraction after first-pass elimination Human recombinant carboxylesterase 1 Herb-drug interaction Inter-individual variability Absorption rate constant Elimination rate constant Liquid chromatography-tandem mass spectrometry Oseltamivir Oseltamivir acid Objective function value Apparent permeability coefficient Plaque forming unit Rat liver microsome Relative standard error Radix Scutellariae Volume of distribution Visual predictive check According to the theory of Traditional Chinese Medicine (TCM), influenza is categorized as an exogenous “warm disease” or “Wen Bing”(Koh, 2010).","label":[[322,333,"Drug"],[334,350,"Drug"],[474,492,"Herb name"],[493,515,"Parameter"],[603,672,"Pathology"]],"Comments":[]}
{"id":6606,"text":"Wen Bing formulas have been used for more than 200 years since their publication in Wen Bing Tiao Bian by Wu Jutong in 1798.","label":[[0,17,"Herb name"],[84,92,"Pathology"]],"Comments":[]}
{"id":6607,"text":"These formulas include Yin-Qiao-San (a formula made up by Fructus Forsythiae, Flos Lonicerae Japonicae, Platycodonis Radix, Menthae Haplocalycis Herba, Radix et Rhizoma Glycyrrhizae, Herba Schizonepetae, Sojae Semen Praeparatum, Fructus Arctii and Reed Rhizome) and Sang-Ju-Yin (a formula made up by Armeniacae Semen Amarum, Fructus Forsythiae, Menthae Haplocalycis Herba, Folium Mori, Chrysanthemi Flos, Platycodonis Radix, Radix et Rhizoma Glycyrrhizae and Reed Rhizome).","label":[[23,35,"Herb name"],[58,76,"Herb name"],[78,103,"Herb name"],[104,122,"Herb name"],[124,150,"Herb name"],[152,181,"Herb name"],[183,202,"Herb name"],[204,227,"Herb name"],[229,243,"Herb name"],[248,260,"Herb name"],[266,277,"Herb name"],[300,323,"Herb name"],[325,343,"Herb name"],[345,371,"Herb name"],[373,384,"Herb name"],[386,403,"Herb name"],[405,423,"Herb name"],[425,454,"Herb name"],[459,471,"Herb name"]],"Comments":[]}
{"id":6608,"text":"Up to now, these two formulas are still the first line herb therapies for treatment and prevention of early-stage influenza in China as recommended by National Health Commission, PRC (National Health Commission, 2018).","label":[[102,123,"Pathology"]],"Comments":[]}
{"id":6609,"text":"As for middle-stage influenza, the recommended formula is Ma-Xing-Shi-Gan-Tang, which is adapted from Shanghan Lun compiled by Zhang Zhongjing before year 220, at the end of the Han dynasty.","label":[[7,29,"Pathology"],[58,78,"Herb name"]],"Comments":[]}
{"id":6610,"text":"This formula is made up by Ephedrae Herba, Armeniacae Semen Amarum, Gypsum Fibrosum, Anemarrhenae Rhizoma, Fritillariae Thunbergii Bulbus, Platycodonis Radix, Radix Scutellariae, Bupleuri Radix and Radix et Rhizoma Glycyrrhizae.","label":[[27,41,"Herb name"],[43,66,"Herb name"],[68,84,"Herb name"],[85,105,"Herb name"],[107,137,"Herb name"],[139,157,"Herb name"],[159,177,"Herb name"],[179,193,"Herb name"],[198,227,"Herb name"]],"Comments":[]}
{"id":6611,"text":"Per the pattern differentiation of TCM, more herbs could be added to the original formulas for specific disease presentations.","label":[],"Comments":[]}
{"id":6612,"text":"The TCM formula commonly used during the Severe Acute Respiratory Syndrome (SARS) epidemic of 2003 in China is the Sang-Ju-Yin formula adjusted by adding Radix Isatidis, Radix Scutellariae and Radix Astragali (Fratkin, 2010).","label":[[41,81,"Pathology"],[154,168,"Herb name"],[170,188,"Herb name"],[193,208,"Herb name"]],"Comments":[]}
{"id":6613,"text":"These Wen Bing formulas were also recommended by TCM experts from Healthy Authority (HA) of Hong Kong for the prophylaxis and treatment of influenza with Oseltamivir (OS).","label":[[6,23,"Herb name"],[139,148,"Pathology"],[154,170,"Drug"]],"Comments":[]}
{"id":6614,"text":"In collaboration with the HA, investigations of the pharmacokinetic and pharmacodynamic interactions between OS and HA recommended Chinese formula, namely CMF1 (a combined formula of Yin-Qiao-San and Sang-Ju-Yin) in both animal and human subjects were performed by our group since 2008 (Chang et al., 2014).","label":[[109,111,"Drug"],[131,138,"Ethnic group"],[155,212,"Herb name"],[216,246,"Study"]],"Comments":[]}
{"id":6615,"text":"To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.","label":[[71,74,"Drug"],[111,128,"Herb name"]],"Comments":[]}
{"id":6616,"text":"Thus, eight herbs, namely Radix Isatidis (Chen et al., 2017), Radix et Rhizoma Glycyrrhizae (Michaelis et al., 2011; Sekine-Osajima et al., 2009; Wolkerstorfer et al., 2009), Radix Scutellariae (Xu et al., 2010), Fructus Forsythiae (Li et al., 2011), Flos Lonicerae Japonicae (Lu et al., 2018), Folium Mori (Savov et al., 2006), Herba Schizonepetae (He et al., 2013) and Fructus Arctii (Hayashi et al., 2010), were selected for further studies based on the flowing cariteria: (i) commonly used in traditional Wen Bing formulas and (ii) the efficacy of the selected herbs in China Pharmacopeaia clearly related to anti-influenza effects based on TCM and (iii) the selected herbs\/their herbal components having antiviral effects on influenza virals in modern pharmacoligical studies.","label":[[26,40,"Herb name"],[62,91,"Herb name"],[175,193,"Herb name"],[213,231,"Herb name"],[251,275,"Herb name"],[295,306,"Herb name"],[329,348,"Herb name"],[371,385,"Herb name"],[509,526,"Herb name"],[628,635,"Pathology"],[731,746,"Pathology"]],"Comments":[]}
{"id":6617,"text":"In addtion, ten relevant marker components in these eight herbs were also selected to help understand the interaction between OS and herbs: epigoitrin from Radix Isatidis; glycyrrhizic acid, liquirtin from Radix et Rhizoma Glycyrrhizae; baicalein, baicalein, wogonin from Radix Scutellariae; phillyrin from Fructus Forsythiae; chlorogenic acid from Flos Lonicerae Japonicae; rutin from Folium Mori and arctiin from Fructus Arctii.","label":[[126,128,"Drug"],[140,150,"Herb name"],[156,170,"Herb name"],[172,189,"Herb name"],[191,200,"Herb name"],[206,235,"Herb name"],[237,246,"Herb name"],[248,257,"Herb name"],[259,266,"Herb name"],[272,290,"Herb name"],[292,301,"Herb name"],[307,325,"Herb name"],[327,343,"Herb name"],[349,373,"Herb name"],[375,380,"Herb name"],[386,397,"Herb name"],[402,409,"Herb name"],[415,429,"Herb name"]],"Comments":[]}
{"id":6618,"text":"OS is the ethyl ester prodrug of oseltamivir acid (OSA, Ro 64–0802), a potent and selective inhibitor of the neuraminidases glycoprotein essential for replication of influenza A and B viruses (He et al., 1999).","label":[[0,49,"Drug"],[51,54,"Drug"],[109,136,"Target"],[166,191,"Pathology"]],"Comments":[]}
{"id":6619,"text":"It is currently marketed under the trade name Tamiflu OS has limited potential for clinically relevant pharmacokinetics interactions with commonly co-administered drugs, such as paracetamol, cimetidine, amoxicllin, aspirin or antacids (Dutkowski et al., 2003).","label":[[46,56,"Drug"],[178,189,"Drug"],[191,201,"Drug"],[203,213,"Drug"],[215,222,"Drug"],[226,234,"Drug"]],"Comments":[]}
{"id":6620,"text":"Comparing with drug-drug interactions of OS, reports on its herb-drug interactions are even fewer.","label":[[41,43,"Drug"],[45,52,"Study"]],"Comments":[]}
{"id":6621,"text":"Effects of herbal supplement and traditional medicines (including extracts from six traditional Cree botanicals, a commercially available Echinacea product, Goldenseal and a traditional Chinese medicine) on the in-vitro activity of human hepatic microsomal-mediated metabolism of OS have been evaluated by Liu et al.","label":[[138,147,"Herb name"],[157,167,"Herb name"],[186,193,"Ethnic group"],[211,219,"Study"],[280,282,"Drug"]],"Comments":[]}
{"id":6622,"text":"(2010).","label":[],"Comments":[]}
{"id":6623,"text":"The findings suggested that there is a potential for health\/herbal supplement used by patients in response to pandemic A\/H1N1 to reduce efficacy of OS, however the potential clinical significance of such interaction was not studied.","label":[[119,125,"Pathology"],[148,150,"Drug"]],"Comments":[]}
{"id":6624,"text":"In addition to limited reports on the herb-drug interactions of OS at pharmacokinetics levels, it was found that the potential interaction could also be at the pharmacodynamics level.","label":[[23,30,"Study"],[64,66,"Drug"]],"Comments":[]}
{"id":6625,"text":"Pomegranate polyphenol extract has not only demonstrated its in-vitro inhibition on the replication of human influenza A\/Hong Kong (H3N2), but has also shown a synergistic effect with OS (Haidari et al., 2009).","label":[[0,30,"Herb name"],[61,69,"Study"],[109,137,"Pathology"],[184,186,"Drug"]],"Comments":[]}
{"id":6626,"text":"Our previous findings (Chang et al., 2014) on pharmacokinetic and pharmacodynamic interactions between OS and CMF1 in both animal and human subjects suggested that: (1) Co-administration of OS (30 mg\/kg, b.i.d, 5 days) and CMF1 (1.95 g\/kg, b.i.d., 5 days) at their human equivalent dose in rats would lead to significantly enhanced antiviral activities although such combination could significantly reduce the systemic exposure of OSA, indicating potential contribution of antiviral activities from CMF1; (2) co-adminstration of OS (75 mg, b.i.d., 5 days) and CMF1 (10 g, b.i.d., 5 days) in 14 healthy male subjects (Zuo et al., 2011) demonstrated similar trend of reduction in plasma concentration of OSA and enhanced antiviral activity against H3N2; (3) metabolism and transport of OS could be significantly inhibited by CMF1\/CMF1 components in a dose-dependent manner, among which arctigenin demonstrated to be the strongest inhibitor as well as a strong antiviral activity with IC Although the absorption and disposition of OS are well identified, the potential effects of herbs\/herbal components on these characteristics remain to be investigated.","label":[[103,105,"Drug"],[110,114,"Herb name"],[190,192,"Drug"],[194,202,"Amount"],[204,209,"Frequency"],[211,217,"Duration"],[223,227,"Herb name"],[229,238,"Amount"],[240,245,"Frequency"],[248,254,"Duration"],[431,434,"Drug"],[499,503,"Herb name"],[529,531,"Drug"],[533,538,"Amount"],[540,545,"Frequency"],[548,554,"Duration"],[560,564,"Herb name"],[566,570,"Amount"],[572,577,"Frequency"],[580,586,"Duration"],[591,615,"Cohort"],[602,606,"Sex"],[702,705,"Drug"],[746,750,"Target"],[784,786,"Drug"],[823,827,"Herb name"],[828,832,"Herb name"],[884,894,"Herb name"],[1028,1030,"Drug"]],"Comments":[]}
{"id":6627,"text":"Therefore, we propose to establish an in-vitro screening platform for investigation of the potential herbs\/herbal components that may have pharmacokinetic and pharmacodynamic interactions with OS.","label":[[38,56,"Study"],[193,195,"Drug"]],"Comments":[]}
{"id":6628,"text":"Such screening platform will be based on available knowledge of absorption, disposition and antiviral activities of OS, and built with our existing models of in-vitro enzymatic reactions of liver microsomes, in-vitro transport using cell lines that over-expressed with P-gp, PEPT1 or OAT, and in-vitro plaque-reduction assay.","label":[[116,118,"Drug"],[158,166,"Study"],[208,216,"Study"],[269,273,"Target"],[275,280,"Target"],[284,287,"Target"],[293,301,"Study"]],"Comments":[]}
{"id":6629,"text":"Raw herbs, namely Radix Isatidis (H1), Radix et Rhizoma Glycyrrhizae (H2), Radix Scutellariae (H3), Fructus Forsythiae (H4), Flos Lonicerae Japonicae (H5), Folium Mori (H6), Herba Schizonepetae (H7) and Fructus Arctii (H8), were purchased from Hong Wang Herbal Drug Store in Hong Kong.","label":[[18,37,"Herb name"],[39,73,"Herb name"],[75,98,"Herb name"],[100,123,"Herb name"],[125,154,"Herb name"],[156,172,"Herb name"],[174,198,"Herb name"],[203,222,"Herb name"]],"Comments":[]}
{"id":6630,"text":"Authentic compounds, epigoitrin (C1), glycyrrhizic acid (C2), liquirtin (C3), baicalein (C4), baicalin (C5), wogonin (C6), phillyrin (C7), chlorogenic acid (C8), rutin (C9) and arctiin (C10), were purchased from Chengdu Must Bio-technology Co. LTD (Chengdu, China).","label":[[21,36,"Herb name"],[38,60,"Herb name"],[62,76,"Herb name"],[78,92,"Herb name"],[94,107,"Herb name"],[109,121,"Herb name"],[123,137,"Herb name"],[139,160,"Herb name"],[162,172,"Herb name"],[177,190,"Herb name"]],"Comments":[]}
{"id":6631,"text":"Content of authentic compounds in the studied herbs were determined using a LC-MS\/MS method which employed an Agilent 6430 triple quadruple mass spectrometer (Agilent Technologies) coupled with electrospray ionization (ESI) source.","label":[],"Comments":[]}
{"id":6632,"text":"MS parameters and separation conditions were optimized for each herb as shown in Table S1.","label":[],"Comments":[]}
{"id":6633,"text":"Contents of C1–C10 in herbs were determined using an external calibration method.","label":[[12,18,"Herb name"]],"Comments":[]}
{"id":6634,"text":"Triplicate samples were prepared for each herb and analyzed.","label":[],"Comments":[]}
{"id":6635,"text":"Finally, the concentrations of C1–C10 in each gram of herbal extracts were summarized in Table S2.","label":[[31,37,"Herb name"]],"Comments":[]}
{"id":6636,"text":"A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.","label":[[52,83,"Herb name"]],"Comments":[]}
{"id":6637,"text":"The content (w\/w) of C4, C5 and C6 in RS were 2.0%, 48.0% and 0.4%, respectively, as quantified by our LC–MS\/MS method.","label":[[21,23,"Herb name"],[25,27,"Herb name"],[32,34,"Herb name"],[38,40,"Herb name"]],"Comments":[]}
{"id":6638,"text":"Oseltamivir (OS) and oseltamivir acid (OSA) (both purity ≥99%) were kindly provided by Roche Company (St. Louis, MO, USA).","label":[[0,16,"Drug"],[21,43,"Drug"]],"Comments":[]}
{"id":6639,"text":"Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.","label":[],"Comments":[]}
{"id":6640,"text":"Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.","label":[],"Comments":[]}
{"id":6641,"text":"Co. (Milwaukee, WI, USA).","label":[],"Comments":[]}
{"id":6642,"text":"For cell culture, Dulbecco’s modified Eagle’s medium, 0.25% trypsin-EDTA, fetal bovine serum, penicillin-streptomycin, hank’s balanced salt solution (HBSS), sodium butyrate and non-essential amino acids were purchased from Gibco BRL Co. Ltd (Carlsbad, CA, USA) and lifer Technologies (Grand Island, NY, USA).","label":[],"Comments":[]}
{"id":6643,"text":"Six-well plates with Transwell MDCK-WT and MDCK-MDR1 cells were generously provided by Prof. P. Borst (The Netherlands Cancer Institute).","label":[],"Comments":[]}
{"id":6644,"text":"For cell culture, MDCK-WT and MDCK-MDR1 cells were cultured in Dulbecco’s modified Eagle’s medium at 37 °C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, in an atmosphere of 5% CO Caco-2 cells were purchased from American Type Culture Collection.","label":[],"Comments":[]}
{"id":6645,"text":"For cell culture, Caco-2 cells were cultured in Dulbecco’s modified Eagle’s medium at 37 °C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 100 U\/mL of penicillin, and 100 U\/mL of streptomycin in an atmosphere of 5% CO Empty vector (mock) transfected and human organic anion transporter 3 (OAT3) transfected HEK293 cells were generously provided by Prof. Dafang Zhong (Shanghai Institute of Materia Medica).","label":[[285,319,"Target"]],"Comments":[]}
{"id":6646,"text":"For cell culture, HEK293-MOCK and HEK293-OAT3 were cultured in flasks with Dulbecco’s modified Eagle’s medium at 37 °C, supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 100 U\/mL of penicillin, 100 U\/mL of streptomycin, and 100 μg\/mL of hygromycin B in an atmosphere of 5% CO Diluted rat plasma (10%) of 400 μL was spiked with 4 μL herb\/herbal components (H1–H8: 50 mg\/mL; C1–C10: 10 mg\/mL), which were dissolved in DMSO (control group was spiked with only DMSO).","label":[],"Comments":[]}
{"id":6647,"text":"These reaction mixtures were pre-incubated for 5 min in a 37 °C water bash.","label":[],"Comments":[]}
{"id":6648,"text":"Then, 40 μL of 10 μg\/mL OS was added to initialize the reaction.","label":[[24,26,"Drug"]],"Comments":[]}
{"id":6649,"text":"The final mixture was incubated for 30 min and terminated by adding 400 μL ice-cold acetonitrile and 200 μL internal standard (100 ng\/mL of albuterol in water).","label":[],"Comments":[]}
{"id":6650,"text":"After vertex and centrifugation at 13,000 rpm for 10 min, 2 μL of the supernatant was injected for LC\/MS\/MS analysis.","label":[],"Comments":[]}
{"id":6651,"text":"Thaw rat liver microsome (RLM) slowly on ice and adjust concentration to 10 mg\/mL.","label":[],"Comments":[]}
{"id":6652,"text":"The incubation system was composed of: (1) 176 μL of 50 mM PBS; (2) 2 μL of 100 μg\/mL OS and 2 μL of 100 μg\/mL herb components (C1 to C10); (3) 10 μL of 10 mg\/mL RLM.","label":[[86,88,"Drug"],[128,137,"Herb name"]],"Comments":[]}
{"id":6653,"text":"Pre-incubate the above mixture in water bath for 5 min.","label":[],"Comments":[]}
{"id":6654,"text":"Initiate the reactions with the addition of 10 μL of 20 mM NADPH regenerating system (NADP Thaw hCE1 slowly on ice and diluted to 40 μg\/mL with 50 mM PBS (pH 7.4).","label":[[96,100,"Target"]],"Comments":[]}
{"id":6655,"text":"Pre-incubate hCE1 in 37 °C water bath for 5min.","label":[[13,17,"Target"]],"Comments":[]}
{"id":6656,"text":"The hydrolysis reaction was initiated by the addition of OS and herbal components (200 μL, final concentration 10 μM) for 60 min.","label":[[57,59,"Drug"]],"Comments":[]}
{"id":6657,"text":"The reaction was terminated by adding 5 μL of 8 mg\/mL dichlorvos and then mixed with 600 μL PBS.","label":[],"Comments":[]}
{"id":6658,"text":"Vortex the samples, and centrifuge at 13, 000 rpm for 10 min.","label":[],"Comments":[]}
{"id":6659,"text":"Pipette 100 μL supernatant into 50 μL internal standard (100 ng\/mL albuterol in water) and 100 μL water.","label":[],"Comments":[]}
{"id":6660,"text":"After vortex and centrifugation, 10 μL of supernatant were injected for LC\/MS\/MS analysis.","label":[],"Comments":[]}
{"id":6661,"text":"The cytotoxicity of OS combined with selective herbs\/herbal components to interfere with the growth of MDCK-WT, MDCK-MDR1, Caco-2, HEK293-MOCK and HEK293-OAT3 cells were determined by MTT assay.","label":[[20,22,"Drug"],[117,121,"Target"],[154,158,"Target"]],"Comments":[]}
{"id":6662,"text":"The cells were seeded onto a 96-well plate at a density of 5 × 10 To identify potential modification on P-gp mediated transport of OS by herbs\/herbal components, the A to B transport study of OS with or without herbs\/herbal components was carried out in MDCK-WT and MDCK-MDR1 cell lines.","label":[[104,108,"Target"],[131,133,"Drug"],[192,194,"Drug"]],"Comments":[]}
{"id":6663,"text":"Cells were rinsed twice and equilibrated with HBSS at 37 °C before experiment.","label":[],"Comments":[]}
{"id":6664,"text":"Test solutions (30 μg\/mL OS dissolved in HBSS with or without herbs\/herbal components) were loaded into the apical side of chamber (AP, 1.5 mL volume).","label":[[25,27,"Drug"]],"Comments":[]}
{"id":6665,"text":"400 μL of solution was collected from basolateral side (BL, 2.6 mL in volume) at 30 min, 60 min, 90 min, and 120 min, followed by replacing with equal volume of blank HBSS to the receiver chamber, and finally subjected to analysis for OS by LC\/MS\/MS.","label":[[235,237,"Drug"]],"Comments":[]}
{"id":6666,"text":"Caco-2 cells were used for the screening of herbs\/herbal components to determine their effect on the uptake of OS via PEPT1.","label":[[111,113,"Drug"],[118,123,"Target"]],"Comments":[]}
{"id":6667,"text":"Caco-2 cells grown on the 6-well plates for 7 days were rinsed with HBSS containing 10 mM Gly-Sar twice and pre-incubated for 20 min before uptake study.","label":[],"Comments":[]}
{"id":6668,"text":"After pre-incubation, test solutions (30 μg\/mL OS dissolved in HBSS with or without herbs\/herbal components) were added to initiate uptake.","label":[[47,49,"Drug"]],"Comments":[]}
{"id":6669,"text":"The uptake of OS increased linearly up to 1 min.","label":[[14,16,"Drug"]],"Comments":[]}
{"id":6670,"text":"Thus, the Caco-2 cells were incubated at 37 °C for 1 min and then washed 5 times with 2 mL of ice-cold blank HBSS to terminate the uptake of OS.","label":[[141,143,"Drug"]],"Comments":[]}
{"id":6671,"text":"The cells were lysed by the multigelation method and the content of OS in cells was then analyzed by LC\/MS\/MS.","label":[[68,70,"Drug"]],"Comments":[]}
{"id":6672,"text":"HEK293-MOCK and HEK293-OAT3 cells were used to illustrate the effect of the herbs\/herbal components on the modification of OS via OAT3.","label":[[23,27,"Target"],[123,125,"Drug"],[130,134,"Target"]],"Comments":[]}
{"id":6673,"text":"Cells were washed twice with HBSS on day 3 or 4 and pre-incubated at 37 °C for 20 min.","label":[],"Comments":[]}
{"id":6674,"text":"Experiments were initiated by the addition of HBSS containing OS with or without herbs\/herbal components and terminated by removing the solutions and washed 3 times carefully with ice-cold HBSS.","label":[[62,64,"Drug"]],"Comments":[]}
{"id":6675,"text":"Subsequently, the cells were lysed by the multigelation method and the supernatant after processing was injected to LC\/MS\/MS for analysis of OS.","label":[[141,143,"Drug"]],"Comments":[]}
{"id":6676,"text":"The experiments were carried out after approval by the Animal Ethics Committee of The Chinese University of Hong Kong (Ref No.","label":[[86,93,"Ethnic group"]],"Comments":[]}
{"id":6677,"text":"14-171-MIS).","label":[],"Comments":[]}
{"id":6678,"text":"Male Sprague-Dawley (SD) rats (weighting ~250 g) used in the experiment were provided by Laboratory Animal Services Center of The Chinese University of Hong Kong (Hong Kong SAR, People’s Republic of China).","label":[[0,4,"Sex"],[130,137,"Ethnic group"]],"Comments":[]}
{"id":6679,"text":"Solutions of oseltamivir (OS, 7.5 mg\/mL) were freshly prepared before each experiment by dissolving OS in deionized water.","label":[[13,24,"Drug"],[26,28,"Drug"],[30,39,"Amount"],[100,102,"Drug"]],"Comments":[]}
{"id":6680,"text":"RS extract was prepared as a suspension (Low dose: 75 mg\/g; High dose: 150 mg\/g) in water containing 5% (w\/w) PEG400.","label":[[0,10,"Herb name"],[51,58,"Amount"],[71,79,"Amount"]],"Comments":[]}
{"id":6681,"text":"A total of 60 rats were randomly divided into 6 groups (G1 to G6), with 10 rats in each group, to receive various oral drug treatments for 5 days.","label":[[11,18,"Cohort"],[24,93,"Study"],[135,145,"Duration"]],"Comments":[]}
{"id":6682,"text":"On 9AM and 6PM of each day, rats in G1 to G3 received a dose of 30 mg\/kg OS and rats in G4 to G6 were given water only at the same time.","label":[[64,72,"Amount"],[73,75,"Drug"]],"Comments":[]}
{"id":6683,"text":"On 11AM and 8PM of each day, the doses administered to rats were water for G1 and G6, 300 mg\/kg RS for G2 and G4, and 600 mg\/kg RS for G3 and G5, respectively.","label":[[86,95,"Amount"],[96,98,"Herb name"],[118,127,"Amount"],[128,130,"Herb name"]],"Comments":[]}
{"id":6684,"text":"On Day 4, 1 h after receiving the 11AM-dose, a jugular vein cannulation surgery was performed on rats under light anesthesia.","label":[],"Comments":[]}
{"id":6685,"text":"After surgery, the rats were placed individually into metabolic cages and allowed to recover, with overnight fasting but free access to water.","label":[],"Comments":[]}
{"id":6686,"text":"After the 9AM dosing on Day 5, 10 blood samples (0.2 mL each) were obtained via the catheter at 0, 15, 30, 60, 90, 120, 180, 240, 360 and 480 min post dose.","label":[],"Comments":[]}
{"id":6687,"text":"After each blood sampling, 0.2 mL of normal saline containing 20 units\/mL of heparin were immediately injected into the catheter to flush the catheter.","label":[],"Comments":[]}
{"id":6688,"text":"The urine samples were collected over 8 h post-dose and combined with the volume of water used for rinsing the metabolic cage.","label":[],"Comments":[]}
{"id":6689,"text":"The collected urine samples were stored at −80 °C until analysis.","label":[],"Comments":[]}
{"id":6690,"text":"At 30 min following the 8PM dose on Day 5, the rats were anesthetized and about 10 mL of blood were collected from rats’ inferior vena for determination of antiviral activity.","label":[],"Comments":[]}
{"id":6691,"text":"The blood samples collected in G6 (group with no treatment) served as control.","label":[],"Comments":[]}
{"id":6692,"text":"Rat plasma or diluted urine samples were purified with a Waters Oasis MCX extraction cartridge (1 cc, 30 mg) per the following procedure: 1) Equilibrate the cartridge with 1 mL methanol and 1 mL H An Agilent 6430 triple quadruple mass spectrometer (Agilent Technologies) coupled with electrospray ionization (ESI) source was employed for detecting OS and OSA in the above-mentioned bio-samples.","label":[[348,350,"Drug"],[355,358,"Drug"]],"Comments":[]}
{"id":6693,"text":"MS parameters and separation conditions were optimized for each kind of bio-samples.","label":[],"Comments":[]}
{"id":6694,"text":"Generally, nitrogen was used as the de-solvation (10 L\/min) and nebulizer gas (50 psi) and the source parameters were: ESI (+), temperature 350 °C, source voltage 4000 V and delta EMV 400 V. Chromatographic separations were achieved by a SunFire C The MDCK SIAT-1 cell line was grown in DMEM, high glucose, pyruvate supplemented with 10% fetal bovine serum, 2 mM L-glutamine (all from Thermo Fisher Scientific, Massachusetts, USA) at 37 °C in 5% CO MDCK SIAT-1 cells were seeded at 6.25 × 10 For inhibition of OS hydrolysis, OSA formation rate were calculated by the molar amount of OSA divided by reaction time and volume of rat plasma (or protein amount of RLM and hCE1).","label":[[510,512,"Drug"],[525,528,"Drug"],[583,586,"Drug"]],"Comments":[]}
{"id":6695,"text":"For P-gp transport study, apparent permeability coefficient (P Selection of herb for verification of the potential herb-drug interaction (HDI) in rats.","label":[[4,8,"Target"]],"Comments":[]}
{"id":6696,"text":"To comprehensively compare the influential of herbs\/herbal components on the inhibition of OS hydrolysis and the transport\/uptake of OS, the results from each experiment were expressed as a fold change (FC) by the following equation: Nonlinear mixed-effects modeling was performed with NONMEM (version 7.4; ICON Development Solutions, Ellicott City, Maryland, USA) and Perl-speaks-NONMEM (version 4.8.1; Uppsala University, Uppsala, Sweden).","label":[[91,93,"Drug"],[133,135,"Drug"]],"Comments":[]}
{"id":6697,"text":"The structural model building was performed under ADVAN 6 with the first order conditional method with interaction (FOCE + I), and the variance–covariance matrix was calculated using the default method to estimate the relative standard error (RSE) of each parameter.","label":[],"Comments":[]}
{"id":6698,"text":"The final model was established in a stepwise manner per the following criteria: (1) minimum of objective function value (OFV); (2) successful both for minimization and covariance calculation; (3) RSE < 50%; (4) only accepting additional parameter when the dropped OFV>3.84 (p < 0.05); (5) shrinkage < 50% for accepting the addition of an inter-individual variability (IIV) of one parameter.","label":[],"Comments":[]}
{"id":6699,"text":"All models were also visually qualified based on goodness-of-fit of plasma concentration–time profiles and accumulative urine amount of OS and OSA on an individual and population level.","label":[[136,138,"Drug"],[143,146,"Drug"]],"Comments":[]}
{"id":6700,"text":"A visual predictive check (VPC) and bootstrap procedure (n = 1000) were used as internal validation tools to ensure the ruggedness and predictability of the final model.","label":[],"Comments":[]}
{"id":6701,"text":"From the bootstrap estimation, the median and 2.5th and 97.5th percentiles were obtained to represent the non-parametric 95% confidence intervals (CI).","label":[],"Comments":[]}
{"id":6702,"text":"Inhibition effects of the eight herb extracts (H1 to H8) and their ten marker components (C1 to C10) on the hydrolysis of OS were evaluated in rat plasma, RLM and hCE1 by incubating OS in presence and absence of studied herb\/herbal components.","label":[[90,92,"Herb name"],[96,99,"Herb name"],[122,124,"Drug"],[182,184,"Drug"]],"Comments":[]}
{"id":6703,"text":"The incubation system for rat plasma contains 1 μg\/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb\/herbal components.","label":[],"Comments":[]}
{"id":6704,"text":"The results were demonstrated in Fig.","label":[],"Comments":[]}
{"id":6705,"text":"S1.","label":[],"Comments":[]}
{"id":6706,"text":"The formation rate of OSA could be significantly suppressed by all the herb\/herbal components.","label":[[22,25,"Drug"]],"Comments":[]}
{"id":6707,"text":"Among all the selected herbs, H4 (Fructus Forsythiae) and H8 (Fructus Arctii) can almost completely inhibit the hydrolysis of OS (>97% OS remained after 60 min incubation).","label":[[34,52,"Herb name"],[62,76,"Herb name"],[126,128,"Drug"],[135,137,"Drug"]],"Comments":[]}
{"id":6708,"text":"For the herbal components, C4 and C6, which are the marker compounds from Radix Scutellariae, could inhibit more than 50% of OS hydrolysis.","label":[[27,29,"Herb name"],[34,36,"Herb name"],[74,92,"Herb name"],[125,127,"Drug"]],"Comments":[]}
{"id":6709,"text":"Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.","label":[],"Comments":[]}
{"id":6710,"text":"S2 and S3), in which both C1 and C2 significantly suppressed the OS hydrolysis.","label":[[26,28,"Herb name"],[33,35,"Herb name"],[65,67,"Drug"]],"Comments":[]}
{"id":6711,"text":"This suggests the hydrolysis of OS in RLM are mainly mediated by an analogue of hCE1.","label":[[32,34,"Drug"]],"Comments":[]}
{"id":6712,"text":"Cytotoxicity test of herbs\/herbal components on MDCK cells (MDCK-WT and MDCK-MDR1) and HEK293 cells (HEK293-MOCK and HEK293-OAT3) did not show significant cytotoxicity at concentrations up to 1 mg\/mL.","label":[[124,128,"Target"],[192,199,"Amount"]],"Comments":[]}
{"id":6713,"text":"In addition, the corresponding ten tested herbal components did not show significant cytotoxicity on MDCK-WT, MDCK-MDR1, HEK29-MOCK and HEK293-OAT3 cells at concentrations up to 100 μg\/mL.","label":[[178,187,"Amount"]],"Comments":[]}
{"id":6714,"text":"The viability of all cells was more than 80% in presence of both oseltamivir (30 μg\/mL) and herbs\/herbal components at the studied highest concentrations.","label":[[65,76,"Drug"],[78,86,"Amount"]],"Comments":[]}
{"id":6715,"text":"The maximum concentrations of herbs and herbal components for transport and uptake studies were therefore set at 1 mg\/mL and 100 μg\/mL, respectively, for MDCK-WT, MDCK-MDR1, HEK29-MOCK and HEK293-OAT3 cells.","label":[[113,120,"Amount"],[125,134,"Amount"]],"Comments":[]}
{"id":6716,"text":"As shown in Fig.","label":[],"Comments":[]}
{"id":6717,"text":"S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs\/herbal components during absorption and metabolism.","label":[[20,40,"Study"],[99,101,"Drug"]],"Comments":[]}
{"id":6718,"text":"Since testing HDI in rat models is expensive and time-consuming, we prefer to select one herb, having the most possibility of HDI, to perform in-vivo experiments.","label":[[142,161,"Study"]],"Comments":[]}
{"id":6719,"text":"To make it comparable for the results from the six in-vitro experiments, original values were converted to fold-change (FC) of the control group (no herb\/herbal component interference) and then, the FC values in each experiment were converted into z-scores using z-transform.","label":[[51,71,"Study"]],"Comments":[]}
{"id":6720,"text":"After z-transform, results from different experiments would be comparable since the mean and standard deviation of z-scores is always zero and one, respectively.","label":[],"Comments":[]}
{"id":6721,"text":"The z-scores of each experiment were given in Fig.","label":[],"Comments":[]}
{"id":6722,"text":"1 .","label":[],"Comments":[]}
{"id":6723,"text":"The sum values of absolute z-scores of each herb\/herbal component were given on the top of Fig.","label":[],"Comments":[]}
{"id":6724,"text":"1, right above each sample’s results.","label":[],"Comments":[]}
{"id":6725,"text":"Based on the sum values of absolute z-scores, H3 (Radix Scutellariae), having a highest score (14.6) among all the studied herbs, was selected for further in-vivo experiments.","label":[[46,69,"Herb name"],[155,174,"Study"]],"Comments":[]}
{"id":6726,"text":"Heat map of z-transformed fold-change results (z-scores) for (1) in-vitro inhibition of OS hydrolysis in rat plasma (RP), rat liver microsomes (RLM) and human recombinant carboxylesterase 1 (hCE1); (2) modification on P-gp, PEPT1, OAT3 mediated transport by herbs (H1 to H8) and herbal components (C01 to C10).","label":[[65,73,"Study"],[88,90,"Drug"],[171,196,"Target"],[218,222,"Target"],[224,229,"Target"],[231,235,"Target"],[265,267,"Herb name"],[271,273,"Herb name"],[298,301,"Herb name"],[305,308,"Herb name"]],"Comments":[]}
{"id":6727,"text":"Per the above in-vitro screening in cells and enzymes, we found that H3 (Radix Scutellariae) and its marker components (C4–C6) have a clear hint to interact with OS during the absorption, transportation and metabolism processes.","label":[[14,32,"Study"],[69,92,"Herb name"],[120,122,"Herb name"],[123,125,"Herb name"],[162,164,"Drug"]],"Comments":[]}
{"id":6728,"text":"Thus, a standardized herbal extract of Radix Scutellariae (RS) was utilized to perform an herb-drug interaction study with OS in rats.","label":[[39,62,"Herb name"],[123,125,"Drug"]],"Comments":[]}
{"id":6729,"text":"After 5 days’ administration of the proposed dosages as described in Section 2.6, the plasma-concentration profiles of OS and OSA in groups OS + W (G1), OS+1H (G2) and OS+2H (G3) (Fig.","label":[[6,12,"Duration"],[119,121,"Drug"],[126,129,"Drug"],[140,142,"Drug"],[145,146,"Herb name"],[153,155,"Drug"],[156,158,"Herb name"],[168,170,"Drug"],[171,173,"Herb name"]],"Comments":[]}
{"id":6730,"text":"2 , right) and their corresponding 8-h accumulated amount in urine were obtained.","label":[],"Comments":[]}
{"id":6731,"text":"These data were analyzed using non-compartmental analysis (Table S3).","label":[],"Comments":[]}
{"id":6732,"text":"The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.","label":[[50,52,"Herb name"],[107,109,"Drug"],[131,134,"Drug"]],"Comments":[]}
{"id":6733,"text":"S7).","label":[],"Comments":[]}
{"id":6734,"text":"This can further be verified by the lowered OSA\/OS ratio in rat urine samples after co-administration with RS (Fig.","label":[[44,47,"Drug"],[48,50,"Drug"],[107,109,"Herb name"]],"Comments":[]}
{"id":6735,"text":"S8).","label":[],"Comments":[]}
{"id":6736,"text":"Structure of the population pharmacokinetics model (Left, see Table 1 for full name of each parameter) and mean plasma concentration versus time profiles (Right) after oral administration of OS (30 mg\/kg) in absence (OS + W) and presence of 300 mg\/kg (OS+1H) and 600 mg\/kg of Radix Scutellariae (OS+2H) in rats (n = 10 per group).","label":[[191,193,"Drug"],[195,203,"Amount"],[217,219,"Drug"],[222,223,"Herb name"],[241,250,"Amount"],[252,254,"Drug"],[255,257,"Herb name"],[263,272,"Amount"],[276,294,"Herb name"],[296,298,"Drug"],[299,301,"Herb name"]],"Comments":[]}
{"id":6737,"text":"Concentrations were given as mean ± SD.","label":[],"Comments":[]}
{"id":6738,"text":"To better understand the interaction mechanism between OS and RS during the absorption and metabolism processes, a population pharmacokinetics (pop-PK) model was developed using both the plasma and urine PK data from groups OS + W, OS+1H and OS+2H.","label":[[55,57,"Drug"],[62,64,"Herb name"],[224,226,"Drug"],[229,230,"Herb name"],[232,234,"Drug"],[235,237,"Herb name"],[242,244,"Drug"],[245,247,"Herb name"]],"Comments":[]}
{"id":6739,"text":"As shown in Fig.","label":[],"Comments":[]}
{"id":6740,"text":"2 (left), the final model was a four compartmental PK model (two compartments for OS and OSA distribution, and another two to represent the reservoirs of OS and OSA in urine) with two absorption compartments (one for directly absorbed amount of OS and one for first-pass eliminated amount of OS).","label":[[82,84,"Drug"],[89,92,"Drug"],[154,156,"Drug"],[161,164,"Drug"],[245,247,"Drug"],[292,294,"Drug"]],"Comments":[]}
{"id":6741,"text":"OS was absorbed from deposit compartment into the central compartment via a first-order process (k  Parameter estimates of the final model in rats after oral administration of 30 mg\/kg OS alone (OS  +  W) or co-administration with 300 mg\/kg RS (OS + 1H)\/600 mg\/kg RS (OS + 2H).","label":[[0,2,"Drug"],[176,184,"Amount"],[185,187,"Drug"],[195,198,"Drug"],[201,203,"Herb name"],[231,240,"Amount"],[241,243,"Herb name"],[245,247,"Drug"],[250,252,"Herb name"],[254,263,"Amount"],[264,266,"Herb name"],[268,270,"Drug"],[273,275,"Herb name"]],"Comments":[]}
{"id":6742,"text":"k Goodness-of-fit plots showed good agreement between predicted and observed concentrations\/amounts with no apparent bias in residual (Figs.","label":[],"Comments":[]}
{"id":6743,"text":"S9 and S10).","label":[],"Comments":[]}
{"id":6744,"text":"The VPC result for the final model is presented in Fig.","label":[],"Comments":[]}
{"id":6745,"text":"3 .","label":[],"Comments":[]}
{"id":6746,"text":"Overall, the 2.5th, 50th and 97.5th percentiles of observed concentrations were within the predicted 95% confidence interval (CI) of these percentiles, suggesting accurate model fitting across different interference groups.","label":[],"Comments":[]}
{"id":6747,"text":"Bootstrapping resulted in median parameter estimates and 95% CIs like the estimates from the original dataset, indicating that the final model provided good precision for parameter estimation (Table 1).","label":[],"Comments":[]}
{"id":6748,"text":"Visual predictive check of the final population pharmacokinetics model developed from 1000 simulations.","label":[],"Comments":[]}
{"id":6749,"text":"The solid line is the median of the observed data and the dotted lines are the 5th and 95th percentiles of the observed data.","label":[],"Comments":[]}
{"id":6750,"text":"The shaded areas are the 95% confidence intervals for the median, 5th percentile and 95th percentiles of the simulated data.","label":[],"Comments":[]}
{"id":6751,"text":"Observed concentrations are displayed as open circles.","label":[],"Comments":[]}
{"id":6752,"text":"OS: oseltamivir; OSA: oseltamivir acid.","label":[[0,15,"Drug"],[17,38,"Drug"]],"Comments":[]}
{"id":6753,"text":"By observing the microscopic morphological changes of MDCK SAIT-1 cells after incubating with serial dilutions of diluted rat plasma for 48 h, it showed that the maximum concentration of plasma preparation could be used for plaque reduction assay was 1:80.","label":[],"Comments":[]}
{"id":6754,"text":"This plasma dilution was used for plaque reduction assay.","label":[],"Comments":[]}
{"id":6755,"text":"The virus plaque reduction results of groups 1–6 (G1 to G6) are shown in Table 2 .","label":[],"Comments":[]}
{"id":6756,"text":"Results were mean values from 3 rats with each plasma sample tested in triplicate.","label":[],"Comments":[]}
{"id":6757,"text":"The no.","label":[],"Comments":[]}
{"id":6758,"text":"of plaque obtained from the G6 (no herb and no oseltamivir administration) was used as reference.","label":[[47,58,"Drug"]],"Comments":[]}
{"id":6759,"text":"The herb only groups (G4 and G5) did not show significant reduction in virus plaque of either H1N1 or H3N2.","label":[[71,106,"Target"]],"Comments":[]}
{"id":6760,"text":"A significant reduction in the number of virus plaque (both H1N1 and H3N2) was observed for oseltamivir treated groups (G1, G2 and G3) and co-administration of one\/two times HED of RS extracts with OS did not increase the total antivirus effect.","label":[[41,74,"Target"],[92,103,"Drug"],[160,173,"Frequency"],[181,192,"Herb name"],[198,200,"Drug"]],"Comments":[]}
{"id":6761,"text":"Effect of plasma samples obtained from different treatment groups on influenza A H1N1 and H3N2 virus plaque formation (n = 3).","label":[[69,85,"Pathology"],[90,100,"Pathology"]],"Comments":[]}
{"id":6762,"text":"Note: OS: oseltamivir, W: water, 1H: 300 mg\/kg of Radix Scutellariae, 2H: 600 mg\/kg of Radix Scutellariae.","label":[[6,21,"Drug"],[33,35,"Herb name"],[37,46,"Amount"],[50,68,"Herb name"],[70,72,"Herb name"],[74,83,"Amount"],[87,105,"Herb name"]],"Comments":[]}
{"id":6763,"text":"Student t-test were calculated between W + W (control group) and other groups (**p < 0.01).","label":[],"Comments":[]}
{"id":6764,"text":"— not applicable.","label":[],"Comments":[]}
{"id":6765,"text":"In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb\/herbal components.","label":[[193,195,"Drug"]],"Comments":[]}
{"id":6766,"text":"Plentiful and meaningful information was obtained in different levels and varied degrees.","label":[],"Comments":[]}
{"id":6767,"text":"The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500 μg\/mL) and all the herbal components (100 μg\/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs\/herbal components.","label":[[97,106,"Amount"],[139,148,"Amount"],[182,184,"Drug"]],"Comments":[]}
{"id":6768,"text":"Unexpectedly, we noticed different inhibition trends for C4 and C1 in microsomes and purified enzymes (hCE1) incubation studies.","label":[[57,59,"Herb name"],[64,66,"Herb name"],[103,107,"Target"]],"Comments":[]}
{"id":6769,"text":"C4 showed the strongest inhibition of OS hydrolysis in rat plasma, but no inhibition in microsomes and hCE1 systems.","label":[[0,2,"Herb name"],[38,40,"Drug"],[103,107,"Target"]],"Comments":[]}
{"id":6770,"text":"Among the herbal components, herbal component C1 was the strongest inhibitor for OS hydrolysis in microsomes and hCE1 while in rat plasma it ranked behind C4, C6 and C10.","label":[[46,48,"Herb name"],[81,83,"Drug"],[113,117,"Target"],[155,157,"Herb name"],[159,161,"Herb name"],[166,169,"Herb name"]],"Comments":[]}
{"id":6771,"text":"The composition and enzymes in rat plasma are much more complex than those in microsomes and hCE1.","label":[[93,97,"Target"]],"Comments":[]}
{"id":6772,"text":"Major esterases in plasma are butyrylcholinesterase (BChE), paraoxonase (PON), and carboxylesterase (CES) (Bahar et al., 2012).","label":[[6,15,"Target"],[30,58,"Target"],[60,77,"Target"],[83,105,"Target"]],"Comments":[]}
{"id":6773,"text":"The most abundant plasma protein is albumin, which occasionally shows hydrolyzing activity.","label":[[36,43,"Target"]],"Comments":[]}
{"id":6774,"text":"Esterified compounds are hydrolyzed by these major plasma proteins via different catalytic mechanisms.","label":[],"Comments":[]}
{"id":6775,"text":"The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.","label":[[102,106,"Target"]],"Comments":[]}
{"id":6776,"text":"More work will be performed to clarify the inhibition mechanism of each herbal component.","label":[],"Comments":[]}
{"id":6777,"text":"Since the data from the six in-vitro experiments have different units and intensity ranges, they cannot be compared directly.","label":[[28,48,"Study"]],"Comments":[]}
{"id":6778,"text":"Our current proposed method is to first convert the raw values of each experiment to fold change (FC) of their control groups and then normalize the FC values of each experiment with z-transformation to make the results with different nature comparable between experiments.","label":[],"Comments":[]}
{"id":6779,"text":"Fold change is a measure describing how much a quantity changes going from an initial (control) to a final value and is often used in analysis of gene expression data in microarray and RNA-Seq experiments, for measuring change in the expression level of a gene (Tusher et al., 2001).","label":[],"Comments":[]}
{"id":6780,"text":"In our experiments, FC could be considered as the contribution of herbs\/herbal components in each experiment.","label":[],"Comments":[]}
{"id":6781,"text":"The more FC is far from one (bigger or less than 1), the more likely the studied herbs\/herbal components have an HDI with OS.","label":[[122,124,"Drug"]],"Comments":[]}
{"id":6782,"text":"However, FC still could not be compared between experiments due to varied FC ranges in each experiment.","label":[],"Comments":[]}
{"id":6783,"text":"Inspired by multivariate statistical methods (Varmuza and Filzmoser, 2009), we chose z-transformation, a common normalization method, to normalize the FC values in each experiment to make them having the same distribution of N(0,1).","label":[],"Comments":[]}
{"id":6784,"text":"After such a normalization, the absolute z-score of an herb\/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.","label":[[87,89,"Drug"],[147,149,"Drug"]],"Comments":[]}
{"id":6785,"text":"Thus, the sum of all the absolute z-scores for each herb\/herbal component in the six in-vitro experiments would be an indicator for their HDI potential.","label":[[85,93,"Study"]],"Comments":[]}
{"id":6786,"text":"Based on the in-vitro screening results, RS extract was co-administrated with OS for five days with 6 kinds of combinations.","label":[[13,31,"Study"],[41,51,"Herb name"],[78,80,"Drug"],[85,94,"Duration"]],"Comments":[]}
{"id":6787,"text":"It indicated that co-administration of RS extract with OS could significantly increase the systemic exposure of OS and decrease the systemic exposure of OSA, which is consisted with those observed when co-administration of CMF1 (herbal formula containing RS) with OS (Zuo et al., 2009).","label":[[39,49,"Herb name"],[55,57,"Drug"],[112,114,"Drug"],[153,156,"Drug"],[223,258,"Herb name"],[264,266,"Drug"]],"Comments":[]}
{"id":6788,"text":"The plasma samples from G1 to G6 were further evaluated on influenza virus H1N1 and H3N2.","label":[[59,88,"Target"]],"Comments":[]}
{"id":6789,"text":"The herb-only groups (G4 and G5) showed no virus plaque reduction effect.","label":[[43,55,"Target"]],"Comments":[]}
{"id":6790,"text":"All oseltamivir groups (G1, G2 and G3) could significantly reduce the number of plaques for virus H1N1 and H3N2, but no addition effects were observed when co-administration of OS with RS extracts.","label":[[4,15,"Drug"],[80,111,"Target"],[177,179,"Drug"],[185,196,"Herb name"]],"Comments":[]}
{"id":6791,"text":"The reason that interactions between OS and RS were only observed in pharmacokinetics not pharmacodynamics could be due to different time-points in our current PK and PD evaluations.","label":[[37,39,"Drug"],[44,46,"Herb name"]],"Comments":[]}
{"id":6792,"text":"For PK studies, plasma concentration data from 10 time-points were used, while only one time-point at 2.5 h after oseltamivir administration were used for the PD study.","label":[[114,125,"Drug"]],"Comments":[]}
{"id":6793,"text":"According to the PK profiles for G1, G2 and G3, the concentration of OSA around 2.5 h were approximately calculated using the mean values of those at 2 h and 3 h. The calculated OSA concentrations at 2.5 h for G1, G2 and G3 are 719.4 ± 416.8, 502.8 ± 83.7 and 460.4 ± 143.5 ng\/mL, respectively.","label":[[69,72,"Drug"],[178,181,"Drug"]],"Comments":[]}
{"id":6794,"text":"It showed no significant difference between any two groups for these calculated OSA concentrations in these three groups after performing a two-tailed t-test.","label":[[80,83,"Drug"]],"Comments":[]}
{"id":6795,"text":"Since there was no difference on the OSA concentrations in oseltamivir treated groups and the antivirus effect mainly origins from OSA, it could be deduced that no anti-virus effects difference should be observed for these three groups.","label":[[37,40,"Drug"],[59,70,"Drug"],[131,134,"Drug"]],"Comments":[]}
{"id":6796,"text":"We developed a model to simultaneously fit all the PK and accumulative urine concentration data from groups G1, G2 and G3 which provides several mechanistic and quantitative insights on the interaction between OS and RS as follows: PK of OS exhibited a flip-flop kinetics after oral administration as evidenced by a much slower k  BIO (absorbed fraction) and FP (fraction that escaped first-pass metabolism) were successfully estimated with the urine PK data when the intravenous PK of OS for OS only (G1) and co-administration groups (G2 and G3) are not available.","label":[[210,212,"Drug"],[217,219,"Herb name"],[238,240,"Drug"],[331,354,"Parameter"],[359,407,"Parameter"],[486,488,"Drug"],[493,495,"Drug"]],"Comments":[]}
{"id":6797,"text":"The assumption to use urine PK to estimate BIO is that all (or majority) of the absorbed OS would be collected in urine in the form of OS or its metabolite (OSA), which has already been verified in rats and human studies (He et al., 1999).","label":[[43,46,"Parameter"],[89,91,"Drug"],[135,137,"Drug"],[157,160,"Drug"],[198,220,"Study"]],"Comments":[]}
{"id":6798,"text":"The estimated BIO of OS after 5-days administration of OS in G1 is 23.6%, slightly lower than its reported oral bioavailability (35%) in rats after single dose of 10 mg\/kg of OS (Li et al., 1998).","label":[[14,17,"Parameter"],[21,23,"Drug"],[24,51,"Duration"],[55,57,"Drug"],[107,127,"Parameter"],[163,171,"Amount"],[175,178,"Drug"]],"Comments":[]}
{"id":6799,"text":"Moreover, our current modeling method of integrating plasma and urine PK has an advantage of using less rats (no IV groups needed).","label":[],"Comments":[]}
{"id":6800,"text":"As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.","label":[[50,52,"Herb name"],[54,57,"Parameter"],[61,63,"Drug"],[238,240,"Herb name"],[305,308,"Parameter"],[418,436,"Study"],[441,448,"Study"],[481,488,"Study"],[569,571,"Herb name"],[634,636,"Drug"]],"Comments":[]}
{"id":6801,"text":"Our work sets a good example to demonstrate the feasibility and advantage of using multidisciplinary techniques including experimental science, informatics and pharmacometrics on the investigation of herb-drug interactions.","label":[],"Comments":[]}
{"id":6802,"text":"Potential herb-drug interaction (HDI) between OS and herb\/herbal components observed in the current project serve as a good platform to identify the potential interacted herbs and related mechanism for future clinical monitoring of OS during its integrative medicine practice in human subjects.","label":[[46,48,"Drug"],[232,234,"Drug"]],"Comments":[]}
{"id":6803,"text":"Our six-dimension in-vitro screening identified RS as the herb to have the most HDI potential with OS.","label":[[18,36,"Study"],[48,50,"Herb name"],[99,101,"Drug"]],"Comments":[]}
{"id":6804,"text":"Co-administered RS could inhibit OS hydrolysis during absorption and increase the absorbed fraction of OS, which lead to the increased ratio of OS concentration versus that of OSA in both rat plasma and urine.","label":[[16,18,"Herb name"],[33,35,"Drug"],[103,105,"Drug"],[144,146,"Drug"],[176,179,"Drug"]],"Comments":[]}
{"id":6805,"text":"Never the less, the anti-virus effects of OS were not influenced by co-administered RS.","label":[[42,44,"Drug"],[84,86,"Herb name"]],"Comments":[]}
{"id":6806,"text":"Radix Scutellariae (Root of Scutellaria baicalensis Georgi, Huangqin).","label":[[0,18,"Herb name"],[20,24,"Herb part"],[28,58,"Herb name"]],"Comments":[]}
{"id":6807,"text":"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).","label":[[0,14,"Herb name"],[16,20,"Herb part"],[24,46,"Herb name"]],"Comments":[]}
{"id":6808,"text":"Radix et Rhizoma Glycyrrhizae (Rhizome of Glycyrrhiza uralensis Fisch., Gancao).","label":[[0,29,"Herb name"],[31,38,"Herb part"],[42,63,"Herb name"]],"Comments":[]}
{"id":6809,"text":"Fructus Forsythiae (Fruit of Forsythia suspensa (Thunb.)","label":[[0,18,"Herb name"],[20,25,"Herb part"],[29,47,"Herb name"]],"Comments":[]}
{"id":6810,"text":"Vahl, Lianqiao).","label":[],"Comments":[]}
{"id":6811,"text":"Flos Lonicerae Japonicae (Flower of Lonicera japonica Thunb., Jinyinhua).","label":[[0,24,"Herb name"],[26,33,"Herb part"],[36,53,"Herb name"]],"Comments":[]}
{"id":6812,"text":"Folium Mori (Leaf of Morus alba L., Sangye).","label":[[0,11,"Herb name"],[13,17,"Herb part"],[21,34,"Herb name"]],"Comments":[]}
{"id":6813,"text":"Herba Schizonepetae (Aerial part of Schizonepeta tenuifolia (Benth.)","label":[[0,19,"Herb name"],[21,32,"Herb part"],[36,59,"Herb name"]],"Comments":[]}
{"id":6814,"text":"Briq., Jingjie).","label":[],"Comments":[]}
{"id":6815,"text":"Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).","label":[[0,14,"Herb name"],[16,21,"Herb part"],[25,41,"Herb name"]],"Comments":[]}
{"id":6816,"text":"There are no conflicts of interest among the authors.","label":[],"Comments":[]}
{"id":6817,"text":"Yufeng Zhang, Rat PK, modeling and Manuscript drafting; Chunming Lyu, In-vitro metabolic inhibition and transporter study; Sophia Fong, Transporter study; Qian Wang, Rat PK; Chenrui Li, Rat PK; Nicolas James Ho, Manuscript proof reading; Kay Sheung Chan, Experimental design and plaque reduction assays; Xiaoyu Yan, PK modeling; Zhong Zuo, Experimental design, data analyses and manuscript drafting The following are the Supplementary data to this article: This work is supported by  Supplementary data to this article can be found online at","label":[[70,121,"Study"]],"Comments":[]}
